Suppr超能文献

中国生物医学研究领域的伦理倾销分析及建议解决方案

Analysis of ethics dumping and proposed solutions in the field of biomedical research in China.

作者信息

Liao Bohua, Ma Yonghui, Lei Ruipeng

机构信息

School of Philosophy, Huazhong University of Science and Technology, Wuhan, China.

School of Medcine, Xiamen University, Xiamen, China.

出版信息

Front Pharmacol. 2023 Aug 28;14:1214590. doi: 10.3389/fphar.2023.1214590. eCollection 2023.

Abstract

As international academic exchanges and cooperation deepen, China has actively engaged in international biomedical research collaboration and achieved significant success. However, these accomplishments have been accompanied by ethical controversies and issues, with ethics dumping being a recurrently discussed focus among scholars. This paper reviews ethics dumping incidents in China's biomedical research field and analyzes the underlying causes to answer why China is often susceptible to ethics dumping. We argue that the primary reasons include weak ethical awareness among some researchers, an oversimplified research evaluation system, gaps in relevant ethics governance and oversight mechanisms, and limited capabilities of certain ethics committees. To address these issues, we propose five ethics governance recommendations: establishing refined ethics committees at various levels and types; advancing theoretical and practical research on science and technology ethics governance; strengthening legislation and regulation related to emerging science and technology; emphasizing self-regulation and capacity building of research institutions; and providing special protection and healthcare for victims of ethics dumping. The aim is to enhance China's research supervision system and prevent similar ethics dumping incidents from recurring.

摘要

随着国际学术交流与合作的深入,中国积极参与国际生物医学研究合作并取得了显著成就。然而,这些成就伴随着伦理争议和问题,伦理倾销一直是学者们反复讨论的焦点。本文回顾了中国生物医学研究领域的伦理倾销事件,并分析其背后的原因,以回答为何中国经常容易受到伦理倾销的影响。我们认为主要原因包括一些研究人员的伦理意识薄弱、过于简化的研究评价体系、相关伦理治理和监督机制的差距以及某些伦理委员会的能力有限。为解决这些问题,我们提出五项伦理治理建议:建立各级各类精细化伦理委员会;推进科技伦理治理的理论与实践研究;加强新兴科技相关立法与监管;强调研究机构的自我监管与能力建设;为伦理倾销受害者提供特殊保护和医疗救助。目的是完善中国的研究监管体系,防止类似的伦理倾销事件再次发生。

相似文献

7
Development proposals of Human Research Protection Program.人类研究保护计划的发展提案。
Nurs Ethics. 2021 Jun;28(4):554-562. doi: 10.1177/0969733020952114. Epub 2020 Oct 16.

本文引用的文献

1
Stakeholder Involvement in the Governance of Human Genome Editing in Japan.日本利益相关者对人类基因组编辑治理的参与。
Asian Bioeth Rev. 2023 Apr 26;15(4):431-455. doi: 10.1007/s41649-023-00251-8. eCollection 2023 Oct.
2
China sets new ethics rules for human studies.中国为人体研究制定了新的伦理规则。
Science. 2023 Mar 10;379(6636):970. doi: 10.1126/science.adh4963. Epub 2023 Mar 9.
5
Ethical and regulatory issues in human gene editing: Chinese perspective.人类基因编辑的伦理与监管问题:中国视角。
Biotechnol Appl Biochem. 2020 Nov;67(6):880-891. doi: 10.1002/bab.2032. Epub 2020 Oct 27.
8
China: How science made a superpower.中国:科学如何造就一个超级大国。
Nature. 2019 Oct;574(7776):25-28. doi: 10.1038/d41586-019-02937-2.
9
Reboot ethics governance in China.重启中国的伦理治理。
Nature. 2019 May;569(7755):184-186. doi: 10.1038/d41586-019-01408-y.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验